Microlyte in Prevention of SSI After Open Ventral Hernia Repair

ClinicalTrials.gov ID: NCT05093894

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05093894. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Multicenter Randomized Study of Microlyte - AG Bioresorbable Matrix in the Prevention of Surgical Site Infection After Open Ventral Hernia Repair

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Participants who are scheduled to have open ventral hernia repair (OVHR) will be asked to take part in this study. The purpose of this study is to find out if placing Microlyte (which is a dissolvable sheet coated in silver) on the surgical incision is better than placing nothing on the surgical incision when it comes to decreasing the chance of surgical site infections. The study device has been cleared by the Food and Drug Administration (FDA) for use on surgical incisions. A total of 280 participants will be included in the study. Participation will last for about 90 days.

Study identification

NCT ID: NCT05093894
Recruitment status: Withdrawn
Study type: Interventional
Phase: Not applicable
Lead sponsor: Prisma Health-Upstate; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Ventral Hernia

Interventions

Group 1 Device

Device

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 14, 2021 (Actual)
Primary completion: Oct 6, 2022 (Actual)
Completion: Oct 6, 2022 (Actual)
Last update posted: Oct 10, 2022

2021 – 2022

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 3

Facility	City	State	ZIP	Site status
Mission Hospital/HCA Healthcare	Asheville	North Carolina	28801	—
Carolinas Medical Center/Atrium Health	Charlotte	North Carolina	28204	—
Prisma Health	Greenville	South Carolina	29605	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05093894, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 10, 2022 · Synced Nov 13, 2026